| scholarly article | Q13442814 |
| P50 | author | Jiří Vencovský | Q42956790 |
| Paul P Tak | Q89865007 | ||
| P2093 | author name string | Sally Hollis | |
| Zoltán Szekanecz | |||
| Daniëlle M Gerlag | |||
| Martin Braddock | |||
| Mark Layton | |||
| ESCAPE Study Group | |||
| P2860 | cites work | The MOS 36-ltem Short-Form Health Survey (SF-36) | Q26778425 |
| Modified disease activity scores that include twenty-eight-joint counts. Development and validation in a prospective longitudinal study of patients with rheumatoid arthritis | Q34315745 | ||
| Development and validation of the European League Against Rheumatism response criteria for rheumatoid arthritis. Comparison with the preliminary American College of Rheumatology and the World Health Organization/International League Against Rheumati | Q34662758 | ||
| Negative association between the chemokine receptor CCR5-Delta32 polymorphism and rheumatoid arthritis: a meta-analysis | Q35014330 | ||
| Chemokines in joint disease: the key to inflammation? | Q35553416 | ||
| Chemokine and chemokine receptor expression in paired peripheral blood mononuclear cells and synovial tissue of patients with rheumatoid arthritis, osteoarthritis, and reactive arthritis | Q35636896 | ||
| Differential expression of chemokine receptors on peripheral blood, synovial fluid, and synovial tissue monocytes/macrophages in rheumatoid arthritis | Q43607170 | ||
| Measuring health-related quality of life in rheumatoid arthritis: validity, responsiveness and reliability of EuroQol (EQ-5D). | Q44916043 | ||
| American College of Rheumatology. Preliminary definition of improvement in rheumatoid arthritis | Q47643186 | ||
| Once-weekly administration of 50 mg etanercept in patients with active rheumatoid arthritis: results of a multicenter, randomized, double-blind, placebo-controlled trial. | Q51051064 | ||
| Etanercept therapy in rheumatoid arthritis. A randomized, controlled trial. | Q52221782 | ||
| P433 | issue | 11 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | rheumatoid arthritis | Q187255 |
| P304 | page(s) | 3154-3160 | |
| P577 | publication date | 2010-11-01 | |
| P1433 | published in | Arthritis & Rheumatology | Q4797636 |
| P1476 | title | Preclinical and clinical investigation of a CCR5 antagonist, AZD5672, in patients with rheumatoid arthritis receiving methotrexate | |
| P478 | volume | 62 |
| Q90575892 | A bivalent compound targeting CCR5 and the mu opioid receptor treats inflammatory arthritis pain in mice without inducing pharmacologic tolerance |
| Q55496778 | A cytokine protein-protein interaction network for identifying key molecules in rheumatoid arthritis. |
| Q38155907 | Advances in understanding the pathogenesis of autoimmune disorders: focus on chemokines and lymphocyte trafficking |
| Q53191263 | CCR5 deficiency does not reduce hypertensive end-organ damage in mice. |
| Q26824580 | Cellular targeting in autoimmunity |
| Q91199065 | Chemokines in rheumatic diseases: pathogenic role and therapeutic implications |
| Q38188862 | Emerging immunotherapies for rheumatoid arthritis. |
| Q38110963 | Emerging therapies for rheumatoid arthritis |
| Q24202751 | Etanercept for the treatment of rheumatoid arthritis |
| Q38618883 | Inflammatory Cell Migration in Rheumatoid Arthritis: A Comprehensive Review |
| Q37432097 | International Union of Basic and Clinical Pharmacology. [corrected]. LXXXIX. Update on the extended family of chemokine receptors and introducing a new nomenclature for atypical chemokine receptors |
| Q38212169 | Lessons learned from the fate of AstraZeneca's drug pipeline: a five-dimensional framework |
| Q38939820 | Methotrexate monotherapy and methotrexate combination therapy with traditional and biologic disease modifying anti-rheumatic drugs for rheumatoid arthritis: A network meta-analysis. |
| Q28069360 | Neutrophils and Granulocytic MDSC: The Janus God of Cancer Immunotherapy |
| Q46441158 | Overcoming hurdles in developing successful drugs targeting chemokine receptors |
| Q45999111 | Pharmacokinetic and pharmacodynamic evaluation of the novel CCR1 antagonist CCX354 in healthy human subjects: implications for selection of clinical dose. |
| Q54967818 | Phase III, multicentre, double-blind, randomised, parallel-group study to evaluate the similarities between LBEC0101 and etanercept reference product in terms of efficacy and safety in patients with active rheumatoid arthritis inadequately respondin |
| Q47989935 | Protective role for CCR5 in murine lupus nephritis |
| Q90642824 | Role of Chemokines and Chemokine Receptors in Rheumatoid Arthritis |
| Q38647749 | Successes and failures of chemokine-pathway targeting in rheumatoid arthritis |
| Q38026076 | Targeting chemokines in proteinuria-induced renal disease |
| Q39158831 | The Multifunctional Role of the Chemokine System in Arthritogenic Processes |
| Q47390076 | The Role of Macrophages in the Response to TNF Inhibition in Experimental Arthritis |
| Q33746340 | The Utility of In Vitro Data in Making Accurate Predictions of Human P-Glycoprotein-Mediated Drug-Drug Interactions: A Case Study for AZD5672 |
| Q41945153 | The multiple chemokine-binding bovine herpesvirus 1 glycoprotein G (BHV1gG) inhibits polymorphonuclear cell but not monocyte migration into inflammatory sites. |
| Q42326321 | What is the future of CCR5 antagonists in rheumatoid arthritis? |
| Q28742993 | Why CCR2 and CCR5 blockade failed and why CCR1 blockade might still be effective in the treatment of rheumatoid arthritis |
Search more.